TWI564558B - 用於判定哺乳類動物細胞的心臟發展潛能之方法以及用於執行該方法之裝置 - Google Patents

用於判定哺乳類動物細胞的心臟發展潛能之方法以及用於執行該方法之裝置 Download PDF

Info

Publication number
TWI564558B
TWI564558B TW099116051A TW99116051A TWI564558B TW I564558 B TWI564558 B TW I564558B TW 099116051 A TW099116051 A TW 099116051A TW 99116051 A TW99116051 A TW 99116051A TW I564558 B TWI564558 B TW I564558B
Authority
TW
Taiwan
Prior art keywords
cell
carpi
genes
cells
gene
Prior art date
Application number
TW099116051A
Other languages
English (en)
Other versions
TW201105965A (en
Inventor
安得利 德爾日克
阿達 培發爾
羅蘭 戈登貝爾斯福特
文錫安 高生
克斯秦 豪姆西
Original Assignee
馬友教育研究基金會
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 馬友教育研究基金會 filed Critical 馬友教育研究基金會
Publication of TW201105965A publication Critical patent/TW201105965A/zh
Application granted granted Critical
Publication of TWI564558B publication Critical patent/TWI564558B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/73—Hydrolases (EC 3.)
    • C12N2501/734—Proteases (EC 3.4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00—Reactions of nucleic acids characterised by
    • C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/113—PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2561/00—Nucleic acid detection characterised by assay method
    • C12Q2561/101—Taqman
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2561/00—Nucleic acid detection characterised by assay method
    • C12Q2561/113—Real time assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Description

用於判定哺乳類動物細胞的心臟發展潛能之方法以及用於執行該方法之裝置
本發明係相關於透過注入哺乳動物細胞對心臟疾病之治療。本發明尤其是相關於一種定量評估哺乳動物細胞的心肌生成潛力的方法，藉此可以對修復心臟成功的機率作出良好的預測。本發明也是相關於一種定量評估哺乳動物細胞的心肌生成潛力的修正，及目標在細胞分化的心肌基因性潛力治療的方法；以及相關於一種電腦裝置，其至少包含一個處理器，以及一個存入有一個或多個非神經網路(non-neural network)程式且與該處理器相耦接的記憶體，其中，該程式使得處理器執行一種方法，該方法包含計算心臟發展潛能指標(CARPI)者。
儘管現在病患管理已有各種進步，但是心血管疾病仍是世界上主要不可治療又易致死之疾病。相對於其他各類修復能力高的組織，心臟組織很容易受到難以修復的損害。現今在臨床上進行以解決心臟病症的是，以細胞為基礎的再生性心血管藥物。
近來幹細胞生物學的長足發展，擴大了最新實行的醫療模式， 即從傳統上病症減輕擴展到修復治癒。典型的是，臨床經驗皆係根據基於利用未經改變狀態之成人幹細胞者。第一代生物製劑是天生人類幹細胞，其被認為係方便獲得的細胞型。已被證明的是，有一些病患在給予天生人類幹細胞後能夠獲得改善。對人類心臟移植天生人類細胞技術情形，在Abdel-Latif A等人的文獻：‘Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis.’ Arch Intern Med. (2007) 167：989-997，以及文中的引用中都有被特別描述到。
為了改善臨床的效果，各種第二代幹細胞治療法發展出在植入病患之前，先將天生人類幹細胞引導至心肌細胞世系(lineage)中。為再生心臟而使用心肌前驅性細胞〔如：心肌潛能細胞，Cardiopoietic cells〕的概念在Behfar等人，在「Guided stem cell cardiopoeisis：Discovery and translation.J.Mol.and Cell.Cardiology(2008)45：523-529」的評論中也有所提及。
心肌潛能細胞(Cardiopoietic cells)具有獨特的表現型：他們的特徵是細胞所產生的Nkx2.5及MEF2C多肽鏈產生入核作用(nuclear translocation)以及無法偵測到肌節蛋白質之存在之特性。心肌潛能細胞處在一種細胞中間表現型的狀態，即它們歸屬於心肌細胞世系(lineage)，然而卻尚未分化完全。心肌潛能細胞所表現的肌節蛋白質無法被偵測到，是其能與收縮肌細胞及含有肌節蛋白質的類心肌細胞有所區分的一項特徵(請參閱Chunhui Xu(US 2005/0164382)及Lough et al(US 2002/0061837))。
轉錄因子蛋白質產量的增加，並不能預測它在細胞的位置，它可能在細胞質也可能在細胞核。Nkx2.5和MEF2C多肽鏈的入核作用是細胞投入往分化成心肌的世系中的必要過程。Behfar A.於(Behfar et al. ‘Derivation of a cardiopoietic population from human mesenchymal stem yields progeny’,Nature Clin.Pract.,Cardiovasc.Med.(2006)3：S78-S82)之中，有更進一步的說明。雖然入核作用可以被免疫細胞染色法或免疫組織化學法來作定性的觀察；觀察細胞中全蛋白質含量的技術，如西方墨點轉漬法(western blotting)和螢光活化細胞分類法(Fluorescence-Activated Cell Sorting,FACS)，並不適合來定量評估多肽鏈在亞細胞的分布狀況。如US 2008/0019944所描述，觀察多肽鏈在亞細胞的分布狀況，不僅需要定性觀察，在產業的角度上，它會受操作者主觀影響，且又是十分費時的。因此，無論是有心肌生成潛力的第一代天生人類幹細胞還是第二代的引導式幹細胞，在注射前皆不易預測其臨床之效果。
對哺乳類動物細胞判斷其心肌生成潛力之定量評估之方法仍有待提出。
本發明現在提供了一個這樣的預測方法，來確定哺乳動物細胞分化成心肌之潛力，這個方法至少包含了定量分析心臟發展潛能指標〔CARPI〕，其為細胞基因表現定量的函數。本發明也關於針對於哺乳動物細胞之細胞分化之潛力，定量評估一種心臟發展潛能改變的治療方法。
定義
在這份說明書的架構中，除非有另外提及，否則下列引號內的術語均定義如後。
一個細胞的「心臟發展潛能」(cardio-generative potential)指的是該細胞成功地分化生出心臟細胞，例如心肌細胞的能力。
心肌潛能細胞(Cardiopoietic cells)是一種發展中的細胞中間表型，亦即它已經在分化成心肌細胞之半途中，只是還沒有完全分化完成。心肌潛能細胞的特徵是它們的Nkx2.5和MEF2C這兩種多肽鏈移位到細胞核中，同時也缺少可被偵測到的肌節蛋白，請參閱(Behfar et al.‘Derivation of a cardiopoietic population from human mesenchymal stem yields progeny’,Nature Clin.Pract.,Cardiovasc.Med.(2006)3：S78-S82)。心肌潛能細胞保留有增殖的能力(proliferative capacity)。心肌潛能細胞可以衍生自幹細胞，例如人類成體間葉幹細胞(Terzic et al.US 2008/0019944)、鼠胚胎幹細胞(Behfar et al,‘Cardiopoietic programming of embryonic stem cells for tumour-free heart repair’J Exp Med 2007 204：405-420)、類胚胎幹細胞(embryonic-like stem cells)、誘導性多潛能幹細胞(inducible pluripotent stem cells)、臍帶血細胞(umbilical cord blood cellsand the like)、留心性幹細胞(resident cardiac stem cells)等等，以及任何其他合適的來源，(只要它們的製造沒有涉及人類胚胎的破壞)。
一種「混合配方」(cocktail’)或「心源物質混合」(cardiogenic cocktail’)指的是含有至少兩種有心肌潛能細胞生成物質(cardiogenic substances)的某種配方。
名詞「促進心肌潛能細胞生成處理」(cardiogenic treatment)在此處是指可以促進細胞分化生成心臟細胞的處理。將前述細胞置於混合配方中就是一個例子。該類混合配方的許多例子都是至少包含以下或其組合之二種物質：生長因子(growth factors)、細胞因子(cytokines)，荷爾蒙(hormones)。前述配方中至少有兩種成分可以選自下述物質：骨骼型態生成 蛋白(bone morphogenetic proteins,BMP)如BMP-1、BMP-2、BMP-5、BMP-6；上皮生長因子(epidermal growth factor,EGF)；紅血球生成素(erythropoietin,EPO)；膠原母細胞生長因子(fibroblast growth factors,FGF)如FGF-1、FGF 4、FGF 5、FGF 12、FGF 13、FGF 15、FGF 20；顆粒性細胞株刺激因子(granulocyte colony stimulating factor,G-CSF)；顆粒性細胞-巨噬細胞株刺激因子(granulocyte-macrophage colony stimulating factor,GM-CSF)；生長分化因子-9(growth differentiation factor-9,GDF-9)；肝細胞生長因子(hepatocyte growth factor,HGF)；類胰島素生長因子(insuline-like growth factor,IGF)如IGF-2；肌肉生長抑制素(myostatin，或稱GDF-8)；神經生長素(neurotrophins)如NT-3、NT-4、NT-1及神經生長因子(nerve growth factor,NGF)；血小板衍生性生長因子(platelet-derived growth factor,PDGF)如PDGF-beta、PDGF-AA、PDGF-BB；血小板生成素(thrombopoietin,TPO)；轉型生長因子-α(transforming growth factor alpha,TGF-α)；轉型生長因子-β(transforming growth factors β,TGF-β)如TGF β 1、TGF β 2、TGF-β 3；血管內皮生長因子(vascular endothelial growth factor,VEGF)如VEGF A、VEGF C；腫瘤壞死因子-α(TNF α)；白血病抑制因子(leukemia inhibitory factor,LIF)；介白素6(interleukin 6，IL-6)；視黃酸(retinoic acid)；基質細胞衍生性因子-1(stromal cell-derived factor-1,SDF-1)；腦衍生性神經生長素(brain-derived neurotrophic factor,BDNF)；骨週素(periostin)；血管張力素II(angiotensin II)；Flt3配體(Flt3 ligand)；神經膠細胞衍生性神經生長素(glial-derived neurotrophic factor)；肝素(heparin)；類胰島素生長因子結合蛋白-3(insulin-like growth factor binding protein-3)；類胰島素生長因子結合蛋白-5(insulin-like growth factor binding protein-5)；介白素-3(interleukin-3)；介白素-8(interleukin-8)；中期激素(midkine)；助孕素(progesterone)；腐胺(putrescine)；幹細胞因子(stem cell factor)；Wnt1；Wnt3a；Wnt5a；硫胱氨酸蛋白酶-4(caspase-4)；趨化素1(chemokine ligand 1)；趨化素2(chemokine ligand 2)；趨化素5(chemokine ligand 5)，趨化素7(chemokine ligand 7)；趨化素11(chemokine ligand 11)；趨化素20(chemokine ligand 20)；肝球蛋白(haptoglobin)；凝集素(lectin)；膽固醇25羥化酶(cholesterol 25-hydroxylase)；突觸融合蛋白-8(syntaxin-8)；突觸融合蛋白-11(syntaxin-11)；血漿銅藍蛋白(ceruloplasmin)；補體1(complement component 1)；補體3(complement component 3)；***素α 6(integrin alpha 6)；溶小體酸性脂肪酶1(lysosomal acid lipase 1)；β-2微球蛋白(β-2 microglobulin)；泛素(ubiquitin)；巨噬細胞移動抑制因子(macrophage migration inhibitory factor)；同纖維蛋白(cofilin)；親環蛋白A(cyclophilin A)；FK506結合蛋白12(FKBP12)；核苷二磷酸激酶(NDPK)；前纖維蛋白1(profilin 1)；血清胱蛋白C(cystatin C)；鈣週期蛋白(calcyclin)；司坦尼氏降鈣素-1(stanniocalcin-1)；***素E-2(PGE-2)；mpCCL2；吲哚胺2,3雙加氧酶(IDO)；可誘導性一氧化氮合成酶(iNOS)；人類白血球抗原-G5(HLA-G5)；巨噬細胞株刺激因子(M-CSF)；促血管生成素(angiopoietin)；胎盤生長因子(PIGF)；單核球趨化蛋白(MCP-1)；細胞外基質分子(extracellular matrix molecules)；C-C趨化素2(CCL2，或稱MCP-1)；C-C趨化素3(CCL3，或稱MIP-1 α)，C-C趨化素4(CCL4，或稱MIP-1 β)，C-C趨化素5(CCL5，或稱RANTES)；C-C趨化素7(CCL7，或稱MCP-3)；C-C趨化素20(CCL20，或稱巨噬細 胞發炎蛋白-3 α，MIP-3 α)；C-C趨化素26(CCL26，或稱嗜伊紅趨化原-3，eotaxin-3)；CX3C趨化素1(CX3CL1，或稱fractalkine)；CXC趨化素5(CXCL5，或稱表皮-嗜中性球活化胜肽，ENA-78)；CXC趨化素11(CXCL11，或稱干擾素誘導性T細胞α趨化因子，i-TAC)；CXC趨化素1(CXCL1，或稱GRO α)；CXC趨化素2(CXCL2，或稱GRO β)；CXC趨化素8(CXCL8，或稱介白素-8，IL-8)；C-C趨化素10(CCL10，或稱干擾素-γ誘發蛋白-10，IP-10)及以上各種物質之任何組合。
一種「受混合配方導引之細胞」(cocktail-guided cell)或一種「被導引往心臟分化之細胞」(cell guided towards cardiac differentiation)指的是培養在混合配方中的細胞。
「分化(Differentiation)」指的是較不特化的細胞轉變為較特化細胞的過程。
「排血分量」(Ejection fraction)指的是在一次心臟搏動中唧出血液的比率。在沒有特別指明的情況下，這一術語排血分量指的是左心室排血分量(left ventricular ejection fraction或簡寫為LVEF)。
在本專利說明書中，單數型的一個、這個，可同時代表其指明個體的複數，除非有明顯的說明並非如此時才是例外。因此，例如：提到「一個幹細胞」可代表單一個單一幹細胞，也可代表兩個或兩個以上的幹細胞；提到「一個試劑」或「一個試藥」就包括了單一種試劑或試藥，以及兩種或兩種以上的試劑或試藥；提到「這個發明」，「一個發明」可以代表這個發明的一個或多個層面，以此類推。
除非另有指明，否則在這個發明中提及的所有的技術或科學 專有名詞均代表其先前廣泛被本產業中之一般技術人員所習知的意義。儘管許多和此處所述相似或相同的方法和材料可以用來練習或測試此發明，以下所記述者則為適當的方法和材料。所有在此提及的出版物、專利申請書、專利以及其他的參考物件都均以其各自全文被引用，且視為每個出版物、專利或專利申請均被明確獨立地全文引用。如有牴觸，將以目前說明書中的說明及定義為適用。另外，這些原料、方法以及範例僅供說明之用，絕非限制本發明之範圍者。
本發明是相關於決定哺乳動物細胞其分化發展成為心肌細胞潛能的方法，其包含心臟發展潛能指標(CARdiac generation Potential Index,CARPI)的評估，該指標為該細胞之基因表現定量的函數。
有利的是，這個心臟發展潛能指標是一種以上述細胞中特定基因的信使核糖核酸表現量為計算基礎的函數。
有利的是，該信使核醣核酸表現的定量係由哺乳動物之以下基因群：Nkx2.5、Tbx5、MEF2C、GATA4、GATA6、Mesp1、FOG1、FOG2以及Flk1同源異型基因(homologues)，以及上述基因的任意組合中選出至少一個者。這些細胞可以是心臟先驅(cardiac progenitor)細胞。這些細胞也可以是成體細胞(somatic)、生殖細胞(germ)、臍帶血(umbilical cord blood)、心臟先驅細胞(cardiac progenitor)、胚胎細胞(embryonic)以及/或是基因改造細胞(genetically modified cells)。
在某些案例中，這些細胞可以來自於一個個體，該細胞的心臟發展潛能指標(CARPI)，會於以心源性物質(cardiogenic)處理之前與之後，皆實施評估。
另一個實施例中，心臟細胞可經由對應不同個體的細胞或者對應不同群體的細胞評估得到一個心臟發展潛能指標(CARPI)而得以互相比較。
在某一個特別受到喜好的實施例中，該心臟發展潛能指標(CARPI)為一多變量方程式(multivariate equation)，其中基因在信使核醣核酸(mRNA)水平的表現之定量值為變數(variable)。
有利的是，該方程式係選自多項式函數(polynomials functions)或超越函數(transcendental functions)或者兩者皆有的函數所組成。
依據一個特別的實施例，其中，其心臟發展潛能指標(CARPI)係被測量來作定量評估一種細胞處理方式之心肌發展潛力(cardiogenic potential)。
依據一個特別的實施例，其中，其心臟發展潛能指標(CARPI)係用來計算其與一種心臟功能參數之相關性者。
本發明也相關於一種電腦裝置，其至少包含一個處理器，以及一個存入有一個或多個非神經網路(non-neural network)程式且與該處理器相耦接的記憶體，其中，該程式使得處理器執行一種方法，該方法包含計算心臟發展潛能指標(CARPI)者。
圖一縱座標以特定單位(arbitrary units,AU)表示CARPI之數值，該數值係分別以人類天生間葉幹細胞(naive human MSC,hMSC)以及已經過多種物質誘導的人類間葉幹細胞(cocktail guided-Hmsc,CP-hMSC)中的基因所轉錄的 mRNA表現量為基礎所計算出來者，橫座標以百分比表示老鼠的梗塞心臟在注射前及注射後LVEF(△EF)的改變量。塗黑的符號代表個別的資料，空心的符號則代表這些個別資料的平均值(Avg)。
複數個骨髓樣本取自罹患有缺血性心臟病而歷經冠狀動脈繞道手術的病人。病人已簽署由制度倫理委員會所認可的告知及同意書。
間葉幹細胞(Mesenchymal stem cells)的收集是，將骨髓放置於塑膠培養盤，清洗十二小時後，再以CD34/CD45/CD133+分子為標記，使用螢光活化細胞分類法(Fluorescence-Activated Cell Sorting,FACS)篩選出黏附細胞。篩選出的間葉幹細胞進一步在37℃含有5%人類血小板釋出液的DMEM培養基(由Mayo Clinic Blood Bank,Rochester,MN提供)中培養及生長。
源自人類骨髓的間葉幹細胞培養於含有人類血小板釋出液的培養基中或培養於含有TGF β-1(2.5ng/ml)、BMP4(5ng/ml)、FGF2(5ng/ml)、IGF-1(50ng/ml)、Activin-A(10ng/ml)、Cardiotrophin(1ng/ml)、α-thrombin(1U/ml)及Cardiogenol C(100nM)多種心源性物質的血清中，以得到具有發展為心肌的潛能細胞族群(cardiopoietic population)。
本發明能夠透過定量評估心肌潛能細胞族群是否有發展成心肌的潛力，它是利用兩個或以上的基因轉錄成RNA的表現量的公式來計算出來的。這項發明排除了定性觀察細胞性質所容易產生的各種困難，如所花時間較長、操作者的主觀性等，它們都是檢視轉錄因子多肽鏈(transcription factor polypeptides)在亞細胞的定位(subcellular location)時會 發生的困難。其中一種可選用的方法就是即時定量反轉錄聚合酶鏈鎖反應(real-time quantitative reverse transcription polymerase chain reaction,qPCR)。這個方法較快得知結果(一天內)，且是經由比較一參考標準來定量，因此操作者本身之主觀性不會影響到結果。此外，不同於免疫染色樣品需要經由螢光顯微鏡逐一檢視評估，使用即時定量反轉錄聚合酶鏈鎖反應(qPCR)可將高達48種不同的樣品(或狀態)於96孔盤一次做每個樣品兩重複的檢測。
為了找出即時定量反轉錄聚合酶鏈鎖反應適合的標記分子(suitable markers for qPCR)，於是將mRNA從經由免疫螢光染色評估後的心肌潛能細胞中抽取出來。
標準參考樣品為來自同一批次的細胞但培養於不含多種心源性物質(cardiogenic cocktail)的培養基中。
表一列出一些的代表心肌轉錄活性的基因，並對這些基因加以評估。
即時定量反轉錄聚合酶鏈鎖反應(qPCR)之操作係使用TaqMan聚合酶鏈鎖反應套組(TaqMan PCR kit)，並搭配Applied Biosystems 7900HT序列偵測系統(由Applied Biosystems,Foster City,CA公司所提供)。TaqMan基因表現反應使用96孔盤，且每樣品三重複。門檻循環數(threshold cycle,CT)的定義為螢光強度累積到一定門檻所需的反應循環數。TaqMan門檻循環數被使用2-△△CT方法轉化為相對的倍數改變，並以將其進行標準化成為家務基因(housekeeping gene)，如GAPDH(P/N 435,2662 0506003)之表達數值進行標準化。
經過處理的細胞所呈現的結果再進行標準化(normalize)變 成與其相對的參考標準所得的結果。
CARPI是先前所述細胞中兩個或以上的基因表現定量結果的函數，其利用試算表Microsoft Excel 2007®(美商微軟公司)計算Nkx2.5、Tbx-5、MEF2C、GATA-4、GATA-6、MESP-1以及FOG-1基因所轉錄的RNA表現量，並加以線性平均。以下為使用的計算公式：
公式裡的i代表所選擇的基因，n代表所有被選擇的基因之總個數，其最小值為2。在這個例子裡，n=7。
起源於人類間葉幹細胞的心肌潛能細胞(hMSC-derived cardiopoietic cells)使用免疫功能不全的裸鼠(由Harlan,Indianapolis,IN公司所提供)來評估其是否有發展成心肌的潛力。所使用之報表格式及使用方式皆係經由相關實驗動物管理及使用委員會所認可者。
心肌梗塞病被製造出來。遵循著盲性設計(blinded design)，將心肌梗塞發生後一個月的裸鼠，在顯微鏡下，注射六十萬個人類天生間葉幹細胞(naive hMSC)或注射六十萬個起源於人類間葉幹細胞的心肌潛能細胞(hMSC-derived cardiopoietic cells)，這些細胞在注射前懸浮於不含血小板釋出液，體積12.5微升(μl)的培養基中，而其注射位置係在左心室前壁心外膜表面之五處(每個注射處2.5微升)。
左心室的功能及構造以胸前心臟超音波(transthoracic echocardiography)持續觀察(儀器提供者為Sequoia 512；Siemens,Malvern,PA 以及VisualSonics Inc,Toronto,Canada)。左心室排血分量(Left ventiicular ejection fraction,LVEF,%)以[(LVVd-LVVs)/LVVd]×100公式計算之，其中LVVd為心臟舒張末期的體積(微升，μl)，LVVs則為心臟收縮末期的體積(微升，μl)。
左心室排血分量(LVEF，△EF)的改變量是以細胞注射前及一個月後的差異為計算方式。
圖一為個別細胞族辟群的CARPI值相對注射上述的個別細胞於老鼠的左心室排血分量(LVEF)的改變量。人類天生間葉幹細胞(圖中以黑色小菱形表示)典型呈現出低的CARPI值，且與細胞注射一個月後老鼠心肌功能無明顯改善相互關聯。值得注意的是，一小批天生具有高CARPI值的人類天生間葉幹細胞也具有好的再生潛力。所有人類天生間葉幹細胞的平均值以大的黑色三角形表示。起源於人類間葉幹細胞的心肌潛能細胞(圖中以黑色小方形表示)典型表現出較高的CARPI值，且與心肌功能的健全增強有所關聯。所有起源於人類間葉幹細胞的心肌潛能細胞平均值以大的白色方形表示。這些平均值係以95%的信賴區間(confidence interval)呈現。
因此，本新發明之發明人證明了注射具有高CARPI值的細胞於心肌梗塞的心臟與其排血分量(ejection fraction,EF)的改變量呈現正相關。因此，CARPI是發展成心肌的潛力的預測性指標。
例2
以多種組合形式的物質TGF β-1(2.5ng/ml)、BMP4(5ng/ml)、Activin-A(5ng/ml)、FGF 2(10ng/ml)、α-thrombin(1U/ml)、IGF-1(50ng/ml)、Cardiotrophin(1ng/ml)以及Cardiogenol C(100nM)處理幹細胞也得到相似的結果。
例3
以多種組合形式的物質TGF β-1(2.5ng/ml)、BMP4(5ng/ml)、Activin-A(5ng/ml)、FGF 2(10ng/ml)、α-thrombin(1U/ml)、IGF-1(50ng/ml)、IL-6(100ng/ml)以及視黃酸(retinoic acid,1μM)處理幹細胞也得到相似的結果。
其他實施例
本發明的描述以及詳細說明，皆係為闡述發明但絕非限制由專利申請範圍所定義的發明範圍。其他的觀點、優勢以及修改都應涵蓋在下列的申請範圍之範疇內。
中文發明摘要
本文件是相關於決定哺乳動物細胞之心臟發展潛能的方法，其包含心臟發展潛能指標(CARPI)的評估，該指標為該細胞之基因表現定量的函數。本發明也相關於一種以細胞分化為處理目的，定量評估心臟發展潛能改變的方法。

Claims (15)

  1. 一種判定哺乳類細胞心臟發展潛能的方法，該方法包含以下之步驟：a 收集兩個或兩個以上哺乳類細胞的基因表現水平，其中該等基因之至少一個基因係選自於以下所組成之群：Nkx2.5、Tbx5、MEF2C、GATA4、GATA6、Mesp1、FOG1、FOG2、Flk1、哺乳動物之上述基因的同源異型基因(homologues)以及上述基因的組合；b 判定心臟發展潛能指標(CARPI)，該心臟發展潛能指標(CARPI)為該細胞之兩個或兩個以上的基因表現定量之函數。
  2. 依據申請專利範圍第1項所述之方法，其中該基因的表現定量是以信使核醣核酸(messenger RNAs,mRNA)的量、功能性核醣核酸(functional RNAs)的量或者兩者之組合的量來定量。
  3. 依據申請專利範圍第2項所述之方法，其中該功能性核醣核酸(functional RNA)為微核醣核酸(microRNA)。
  4. 依據申請專利範圍第2項所述之方法，其中mRNA表現的量係由至少一個選自以下組成之群的基因作定量測量：Nkx2.5、Tbx5、MEF2C、GATA4、GATA6、Mesp1、FOG1、FOG2、Flk1、哺乳動物之上述基因的同源異型基因以及上述基因的任意組合。
  5. 依據申請專利範圍第1項所述之方法，其中該細胞係選自以下組成之群：體細胞、生殖細胞、臍帶血細胞、心臟先驅細胞(cardiac progenitors)、胚胎幹細胞以及上述細胞之任意組合。
  6. 依據申請專利範圍第1項所述之方法，其中該細胞受過基因改造。
  7. 依據申請專利範圍第1項所述之方法，其中該細胞不含可偵測之肌節 蛋白(sacromeric proteins)。
  8. 依據申請專利範圍第1項所述之方法，其中該細胞的CARPI於任何心源性物質處理(cardiogenic treatment)之前與之後，皆實施評估者。
  9. 依據申請專利範圍第8項所述之方法，其中該心源性物質處理包含使該細胞群置入並接觸一種組成物，該組成物包含至少二種可增進細胞的心臟發展潛能(cardiogenic potential)之心源性物質。
  10. 依據申請專利範圍第1項所述之方法，其中該細胞係屬於一種哺乳類動物者。
  11. 依據申請專利範圍第1項所述之方法，其中細胞係來自某一種哺乳動物或來自一群哺乳動物，而該CARPI係被評估且與屬於另一種哺乳動物或另一群哺乳動物之細胞之CARPI值作比較。
  12. 依據申請專利範圍第1項所述之方法，其中該CARPI係以該兩個或兩個以上之基因表現量的線性平均作計算，使用以下公式計算求得： 其中i為所選基因而n為所選基因之總數。
  13. 依據申請專利範圍第1項所述之方法，其中該CARPI係被測量來作定量評估一項處理的心臟發展潛能。
  14. 依據申請專利範圍第1項所述之方法，其中該CARPI係用來計算與心臟功能參數之相關性。
  15. 一種電腦裝置，其包含一個處理器以及一個存入有一個或多個非神經網路(non-neural network)程式且與該處理器相耦接的記憶體，其中該程 式使得處理器執行一種方法，其包含以下步驟：a 收集兩個或兩個以上哺乳類細胞的基因的相對表現水平，其中至少有一個基因係選自由以下組成之群：Nkx2.5、Tbx5、MEF2C、GATA4、GATA6、Mesp1、FOG1、FOG2、Flk1、哺乳動物之上述基因的同源異型基因以及上述基因的組合；b 判定CARPI，而該CARPI係以該兩個或兩個以上之基因之表現量之線性平均值作計算；以及c 顯示該CARPI。
TW099116051A 2009-05-20 2010-05-20 用於判定哺乳類動物細胞的心臟發展潛能之方法以及用於執行該方法之裝置 TWI564558B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
USPCT/US2009/044751 2009-05-20

Publications (2)

Publication Number Publication Date
TW201105965A TW201105965A (en) 2011-02-16
TWI564558B true TWI564558B (zh) 2017-01-01

Family

ID=42316056

Family Applications (1)

Application Number Title Priority Date Filing Date
TW099116051A TWI564558B (zh) 2009-05-20 2010-05-20 用於判定哺乳類動物細胞的心臟發展潛能之方法以及用於執行該方法之裝置

Country Status (13)

Country Link
US (1) US20160298086A1 (zh)
EP (2) EP2433125B1 (zh)
JP (1) JP5921430B2 (zh)
KR (1) KR101808349B1 (zh)
CN (1) CN102498399A (zh)
AU (1) AU2010249821B2 (zh)
BR (1) BRPI1010684A2 (zh)
CA (1) CA2761807C (zh)
IL (1) IL216368A (zh)
NZ (1) NZ595919A (zh)
RU (1) RU2624498C2 (zh)
TW (1) TWI564558B (zh)
WO (1) WO2010135555A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173118B2 (en) 2004-07-30 2012-05-08 Mayo Foundation For Medical Education And Research Compositions consisting essentially of TGF-β, BMP-2 FGF-4, leukemia inhibitory factor, IGF-1, IL-6 and H-α-thrombin
US9765298B2 (en) 2006-07-24 2017-09-19 Mayo Foundation For Medical Education And Research Methods and materials for providing cardiac cells
WO2009145761A1 (en) 2008-05-27 2009-12-03 Mayo Foundation For Medical Education And Research Methods and materials for using cells to treat heart tissue
US9453205B2 (en) * 2009-10-31 2016-09-27 Genesis Technologies Limited Methods for reprogramming cells and uses thereof
KR101874463B1 (ko) * 2009-10-31 2018-08-02 뉴 월드 레보러토리즈 인코포레이티드. 세포의 재프로그램화 방법 및 이의 용도
US20140038291A1 (en) 2009-10-31 2014-02-06 New World Laboratories Inc. Methods for reprogramming cells and uses thereof
US9185690B2 (en) * 2012-02-29 2015-11-10 Sharp Kabushiki Kaisha Allocating and determining resources for a device-to-device link

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI226440B (en) * 2000-09-08 2005-01-11 Kuo Kwang Biotech Corp Predicting survival of patients with squamous cell carcinoma

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020061837A1 (en) 1996-09-05 2002-05-23 Lough John W. Bone morphogenetic protein and fibroblast growth factor compositions and methods for the induction of cardiogenesis
US6324479B1 (en) * 1998-05-08 2001-11-27 Rosetta Impharmatics, Inc. Methods of determining protein activity levels using gene expression profiles
US6218122B1 (en) * 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US7547674B2 (en) * 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
KR101073411B1 (ko) 2001-07-12 2011-10-17 제론 코포레이션 인간 다분화능 줄기 세포로부터 제조된 심근 세포 계통의 세포
EP1497410A4 (en) * 2002-04-01 2005-05-25 Peter K Law CELL TRANSPLANTATION FOR CARDIAC REGENERATION
US20050043260A1 (en) * 2003-04-21 2005-02-24 Baylor College Of Medicine Wnt as a factor for cardiac myogenesis
BRPI0414961A (pt) * 2003-10-03 2006-11-07 Keiichi Fukuda processo de indução da diferenciação de células tronco em células do miocárdio
DE10347436B4 (de) * 2003-10-13 2007-08-02 Johann Wolfgang Goethe-Universität Frankfurt am Main In vitro Verfahren zur Diagnose der kardiovaskulären Funktionalität von Blut-abgeleiteter zirkulierender Vorläuferzellen (BDP)
US20070077578A1 (en) * 2004-03-02 2007-04-05 Primagen Holding B.V. Diagnosis of (a risk of ) disease and monitoring of therapy
US20050277124A1 (en) * 2004-06-10 2005-12-15 White Steven M Cardiac conduction system cells and uses thereof
CA2642381A1 (en) * 2006-02-16 2007-08-23 Fondazione Centro San Raffaele Del Monte Tabor Skeletal muscle periangioblasts and cardiac mesoangioblasts, method for isolation and uses thereof
US9765298B2 (en) 2006-07-24 2017-09-19 Mayo Foundation For Medical Education And Research Methods and materials for providing cardiac cells
WO2008054819A2 (en) * 2006-11-02 2008-05-08 The General Hospital Corporation Cardiovascular stem cells, methods for stem cell isolation, and uses thereof
US20100129915A1 (en) * 2006-11-09 2010-05-27 Deepak Srivastava Methods for inducing cardiomyogenesis
US20110110897A1 (en) * 2008-01-11 2011-05-12 Schwarz Richard P Adult Human Cardiac-Derived Progenitor Cells
EP2100954A1 (en) * 2008-03-10 2009-09-16 Assistance Publique - Hopitaux de Paris Method for generating primate cardiac progenitor cells for clinical use from primate embryonic stem cells, and their applications
WO2009145761A1 (en) * 2008-05-27 2009-12-03 Mayo Foundation For Medical Education And Research Methods and materials for using cells to treat heart tissue

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI226440B (en) * 2000-09-08 2005-01-11 Kuo Kwang Biotech Corp Predicting survival of patients with squamous cell carcinoma

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Rajasingh, et al.,"1-15 STAT3-dependent mouse embryonic stem cell different iation into cardiomyocytes analysis of molecular signaling and therapeutic efficacy of cardiomyocyte precommitted mES transplantation in a mouse model of myocardial infarction" , Circulation research, Vol. 101, 910-918, 2007 *

Also Published As

Publication number Publication date
NZ595919A (en) 2014-01-31
EP2433125A1 (en) 2012-03-28
JP2012527245A (ja) 2012-11-08
IL216368A (en) 2016-02-29
CN102498399A (zh) 2012-06-13
AU2010249821A1 (en) 2011-11-17
US20160298086A1 (en) 2016-10-13
CA2761807A1 (en) 2010-11-25
IL216368A0 (en) 2012-01-31
JP5921430B2 (ja) 2016-05-24
RU2624498C2 (ru) 2017-07-04
EP2433125B1 (en) 2018-11-28
AU2010249821B2 (en) 2015-07-02
EP3524980A1 (en) 2019-08-14
KR101808349B1 (ko) 2017-12-12
AU2010249821A8 (en) 2011-12-08
BRPI1010684A2 (pt) 2017-07-18
KR20120034624A (ko) 2012-04-12
TW201105965A (en) 2011-02-16
WO2010135555A1 (en) 2010-11-25
CA2761807C (en) 2018-01-09
RU2011143063A (ru) 2013-06-27

Similar Documents

Publication Publication Date Title
TWI564558B (zh) 用於判定哺乳類動物細胞的心臟發展潛能之方法以及用於執行該方法之裝置
Fassett et al. Type I collagen structure regulates cell morphology and EGF signaling in primary rat hepatocytes through cAMP-dependent protein kinase A
WO2020243978A1 (zh) 特异性检测人源性基因组dna的引物及其应用
Shi et al. TGF-β/Smad3 stimulates stem cell/developmental gene expression and vascular smooth muscle cell de-differentiation
Tamaki et al. Cardiomyocyte formation by skeletal muscle-derived multi-myogenic stem cells after transplantation into infarcted myocardium
Kammili et al. Generation of novel reporter stem cells and their application for molecular imaging of cardiac-differentiated stem cells in vivo
Kimura et al. Pathological features and pathogenesis of the endomyocardial form of restrictive cardiomyopathy in cats
CA3127507A1 (en) Cell contamination assay
Combes et al. Correction: Single cell analysis of the developing mouse kidney provides deeper insight into marker gene expression and ligand-receptor crosstalk (doi: 10.1242/dev. 178673)
Dewing et al. Defining cardiac cell populations and relative cellular composition of the early fetal human heart
US20120100533A1 (en) Method for determining the cardio-generative potential of mammalian cells
CN103627802B (zh) 检测白血病BCR/ABL m-bcr融合基因相对表达量的引物和方法
EP2460876B1 (en) Method for identifying senescent mesenchymal stem cells
Minter-Dykhouse et al. Uncoupling of proliferative capacity from developmental stage during directed cardiac differentiation of pluripotent stem cells
Wolmarans et al. Single‐Cell Transcriptome Analysis of Human Adipose‐Derived Stromal Cells Identifies a Contractile Cell Subpopulation
Habisch et al. Altered migration and adhesion potential of pro-neurally converted human bone marrow stromal cells
Molina et al. G1 phase lengthening during neural tissue development involves CDC25B induced G1 heterogeneity
CN113106160A (zh) 评估肝谱系细胞成熟度的标志物、双组学试剂盒及构建方法
CN107385020A (zh) 瘦素在人重组fgf21蛋白活性检测中的应用
CN117448457A (zh) 一种人间充质干细胞分化成脂能力的检测方法
Delgado et al. G1 Phase Lengthening During Neural Tissue Development Involves CDC25B Induced G1 Heterogeneity
Taki Modelling the Interaction Between the Disease Microenvironment and Mesenchymal Stem Cells in Systemic Sclerosis
Mah et al. Evaluating cell identity from transcription profiles
Cornwell Application of time-lapse imaging, single-cell tracking, and competing risks analysis to characterise cardiac stem cell growth dynamics
CN115565608A (zh) 一种鉴定样本中间充质干细胞的组织来源的方法及其用途

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees